Daily Caller
RFK’s Calls To Ban One Of Big Pharma’s Most Powerful Tools Rattle Drugmakers Despite Uncertain Political Prospects

From the Daily Caller News Foundation
By Adam Pack
“The primary purpose of pharmaceutical advertising is not to influence consumers, but rather the television networks and news itself”
President-elect Donald Trump’s nomination of Robert F. Kennedy Jr. to helm the Department of Health and Human Services(HHS) is reportedly rattling drugmakers in light of Kennedy’s prior calls to ban pharmaceutical advertising.
If confirmed by the Senate to serve as HHS secretary, Kennedy could marshal the country’s public health agencies to implement his Make America Healthy Again (MAHA) priorities, leading one pharmaceutical industry observer to claim that Kennedy is likely to attempt a ban on direct-to-consumer (DTC) drug advertising. However, any attempt from Kennedy to crack down on pharmaceutical advertising would almost certainly be challenged by drugmakers on First Amendment grounds and may lack the support of Trump and Republican lawmakers who have so far refrained from commenting on Kennedy’s proposal.
“One of the things I’m going to advise Donald Trump to do in order to correct the chronic disease epidemic is to ban pharmaceutical advertising on TV,” Kennedy said to thunderous applause during a Tucker Carlson Live Tour event in Glendale, Arizona, on Oct. 31. “There’s only two countries in the world that allow pharmaceutical advertising on the airwaves. One of them is New Zealand and the other is us and we have the highest disease rate, and we buy more drugs and they’re more expensive than anywhere in the world.”
Spending on DTC pharmaceutical advertising in the United States ballooned to more than $7 billion in 2023, with ad buys on weight loss and diabetes drugs surpassing $1 billion for the first time, according to analysis from MediaRadar.
‘Threat To The Public Good’
“Whilst we have a relatively benign view of RFK’s impact on the Pharma industry, one thing that does worry us is the potential for the U.S. government to ban DTC advertising of drugs,” United Kingdom-based research firm Intron Health wrote in a report excerpted by FiercePharma, a pharmaceutical industry-focused news outlet. “We see this as the biggest imminent threat from RFK and the new Trump administration.”
Kennedy could wield considerable influence over the second Trump administration’s approach to pharmaceutical advertising since the Food and Drug Administration (FDA) — the chief regulator of the pharmaceutical industry’s advertisements — is housed within HHS.
The Biden FDA issued new guidelines on DTC advertising that went into effect on May 20, requiring advertising to state drugs’ side effects and medication risks in a “clear, conspicuous, and neutral manner.” Kennedy called for a review of these guidelines in an op-ed in The Wall Street Journal published on Sept. 5.
During his run for president and as a Trump campaign surrogate, Kennedy claimed that media outlets who receive substantial ad revenue from pharmaceutical companies cannot report on Big Pharma with objectivity.
“The primary purpose of pharmaceutical advertising is not to influence consumers, but rather the television networks and news itself,” according to a statement on Kennedy’s website. “It gives Big Pharma the power to dictate what goes on the news — and what doesn’t — because the networks won’t bite the hand that feeds them.”
“Every other country in the world recognizes that pharma ads represent a threat to the public good,” Kennedy’s website also claims.
Kennedy’s concern that mainstream media has been co-opted by the pharmaceutical industry to buy news outlets’ silence on scrutinizing drugmakers in exchange for ad revenue has been embraced by influential voices in the MAHA movement and other Trump allies.
“The news ad spending from pharma is a public relations lobbying tactic, essentially to buy off the news,” Calley Means, a Kennedy advisor and MAHA advocate, told Tucker Carlson during an interview on Feb 2. “The news is not investigating pharma.”
“No advertising for pharma,” Elon Musk wrote on X on Nov. 19 in response to a post alleging a correlation between the growth of pharmaceutical advertising and rising media bias.
Dr. Jay Bhattacharya, Trump’s nominee to lead the National Institutes of Health, has also argued that media organizations that rake in pharmaceutical advertising revenue should face increased scrutiny when reporting on public health matters. Bhattacharya was notably blacklisted by Twitter before Musk bought the platform over his criticism of the medical establishment’s lockdown approach to the COVID-19 pandemic.
“Another argument against direct-to-consumer advertising by drug companies: Because of DTC ads, drug companies like Pfizer hold a vice grip on the editorial policies of conventional American media, which can ill afford to lose the advertising money,” Bhattacharya wrote on X on May 30, 2023.
Dr. Marty Mackary, Trump’s pick to lead the FDA, has not commented on Kennedy’s proposal nor allegations that the mainstream media has been corrupted by the pharmaceutical industry.
Ban Denies ‘Opportunity To Be Informed’
Although a ban on pharmaceutical advertising would put the U.S. more in line with the rest of the world, an attempted prohibition of the practice by the incoming Trump administration would likely infringe upon the First Amendment’s protection of “commercial speech,” according to Dr. Jeffrey Singer, a general surgeon and senior fellow at the libertarian-leaning Cato Institute.
“His calls to ban pharmaceutical advertising violate the First Amendment right to freely share and exchange information, including scientific information, and infringe on the individual right to self-medicate,” Singer wrote in a statement following Trump’s nomination of Kennedy to serve as HHS secretary.
Banning pharmaceutical advertising would also make Americans less informed about the availability of drugs and their side effects and widen the information gap between medical practitioners and patients, an apparent contradiction to Kennedy’s pledge to fight for Americans’ ability to question the medical establishment and do their own research, Singer told the Daily Caller News Foundation in an interview.
“On the one hand, RFK Jr. says — and I agree with him — that people need to be empowered. They need to do their own due diligence. We should be doing our own investigations,” Singer told the DCNF. “Well, how are you going to do that if you are barred from hearing what the pharmaceutical companies have to say about their medication, and its risks and benefits and side effects, which the FDA requires them to mention?”
“If you want an empowered population of adults to be able to do their own due diligence, you can’t block them from the information that a pharmaceutical [ad] is going to give them — especially when they’re [pharmaceutical companies] allowed to give it to healthcare practitioners,” Singer added. “Denying us the information actually denies us the opportunity to be informed.”
Uncertain Political Prospects
Kennedy’s call to ban pharmaceutical advertising is likely to face skepticism from Republican lawmakers who have traditionally preferred a deregulatory approach to the pharmaceutical industry. The current legislative effort to ban DTC pharmaceutical advertising in Congress has no support from Republican lawmakers.
“Sometimes when I hear his [Kennedy’s] agenda discussed, people are like ‘sounds great — he’s never going to do it’. There’s zero chance he’s going to be able to undo these conflicts of interests and the power of Big Ag and these Republican lawmakers who have a lot of big donors in these industries,” Megyn Kelly told Casey Means, during a Nov. 20 interview on her show about whether Kennedy’s MAHA priorities have enough support to be achieved during the next four years.
The pharmaceutical industry notably has roughly 1800 registered lobbyists in the United States, and industry PACs have doled out more than $15 million to candidates this year.
Trump tried to further regulate pharmaceutical advertising during his first administration by requiring DTC ads on television to include the list price for nearly all drugs covered by Medicare and Medicaid. Three large drugmakers filed suit in response and a federal judge struck down the regulation before it went into effect, ruling that HHS overstepped its authority to compel drugmakers to include their list prices in advertising.
Trump’s transition team did not respond to the DCNF’s inquiry about whether the president-elect supports Kennedy’s advocacy to crack down on pharmaceutical advertising.
The Pharmaceutical Research and Manufacturers of America, a trade association that lobbies on behalf of the pharmaceutical industry, declined to comment on Kennedy’s calls to ban pharmaceutical advertising.
A Kennedy spokesperson did not respond to the DCNF’s request for comment.
Business
Ted Cruz, Jim Jordan Ramp Up Pressure On Google Parent Company To Deal With ‘Censorship’

From the Daily Caller News Foundation
By Andi Shae Napier
Republican Texas Sen. Ted Cruz and Republican Ohio Rep. Jim Jordan are turning their attention to Google over concerns that the tech giant is censoring users and infringing on Americans’ free speech rights.
Google’s parent company Alphabet, which also owns YouTube, appears to be the GOP’s next Big Tech target. Lawmakers seem to be turning their attention to Alphabet after Mark Zuckerberg’s Meta ended its controversial fact-checking program in favor of a Community Notes system similar to the one used by Elon Musk’s X.
Cruz recently informed reporters of his and fellow senators’ plans to protect free speech.
Dear Readers:
As a nonprofit, we are dependent on the generosity of our readers.
Please consider making a small donation of any amount here. Thank you!
“Stopping online censorship is a major priority for the Commerce Committee,” Cruz said, as reported by Politico. “And we are going to utilize every point of leverage we have to protect free speech online.”
Following his meeting with Alphabet CEO Sundar Pichai last month, Cruz told the outlet, “Big Tech censorship was the single most important topic.”
Jordan, Chairman of the House Judiciary Committee, sent subpoenas to Alphabet and other tech giants such as Rumble, TikTok and Apple in February regarding “compliance with foreign censorship laws, regulations, judicial orders, or other government-initiated efforts” with the intent to discover how foreign governments, or the Biden administration, have limited Americans’ access to free speech.
“Throughout the previous Congress, the Committee expressed concern over YouTube’s censorship of conservatives and political speech,” Jordan wrote in a letter to Pichai in March. “To develop effective legislation, such as the possible enactment of new statutory limits on the executive branch’s ability to work with Big Tech to restrict the circulation of content and deplatform users, the Committee must first understand how and to what extent the executive branch coerced and colluded with companies and other intermediaries to censor speech.”
Jordan subpoenaed tech CEOs in 2023 as well, including Satya Nadella of Microsoft, Tim Cook of Apple and Pichai, among others.
Despite the recent action against the tech giant, the battle stretches back to President Donald Trump’s first administration. Cruz began his investigation of Google in 2019 when he questioned Karan Bhatia, the company’s Vice President for Government Affairs & Public Policy at the time, in a Senate Judiciary Committee hearing. Cruz brought forth a presentation suggesting tech companies, including Google, were straying from free speech and leaning towards censorship.
Even during Congress’ recess, pressure on Google continues to mount as a federal court ruled Thursday that Google’s ad-tech unit violates U.S. antitrust laws and creates an illegal monopoly. This marks the second antitrust ruling against the tech giant as a different court ruled in 2024 that Google abused its dominance of the online search market.
Daily Caller
Daily Caller EXCLUSIVE: Trump’s Broad Ban On Risky Gain-Of-Function Research Nears Completion

From the Daily Caller News Foundation
By Emily Kopp
President Donald Trump could sign a sweeping executive order banning gain-of-function research — research that makes viruses more dangerous in the lab — as soon as May 6, according to a source who has worked with the National Security Council on the issue.
The executive order will take a broad strokes approach, banning research amplifying the infectivity or pathogenicity of any virulent and replicable pathogen, according to the source, who requested anonymity to speak candidly about the anticipated executive action. But significant unresolved issues remain, according to the source, including whether violators will be subject to criminal penalties as bioweaponeers.
The executive order is being steered by Gerald Parker, head of the White House Office of Pandemic Preparedness and Response Policy, which has been incorporated into the NSC. Parker did not respond to requests for comment.
Dear Readers:
As a nonprofit, we are dependent on the generosity of our readers.
Please consider making a small donation of any amount here. Thank you!
In the process of drafting the executive order, Parker has frozen out the federal agencies that have for years championed gain-of-function research and staved off regulation — chiefly Anthony Fauci’s former institute, the National Institute of Allergy and Infectious Diseases at the National Institutes of Health.
The latest policy guidance on gain-of-function research, unveiled under the Biden administration in 2024, was previously expected to go into effect May 6. According to a March 25 letter cosigned by the American Society for Microbiology, the Association for Biosafety and Biosecurity International, and Council on Governmental Relations, organizations that conduct pathogen research have not received direction from the NIH on that guidance — suggesting the executive order would supersede the May 6 deadline.
The 2024 guidance altered the scope of experiments subject to more rigorous review, but charged researchers, universities and funding agencies like NIH with its implementation, which critics say disincentivizes reporting. Many scientists say that researchers and NIH should not be the primary entities conducting cost–benefit analyses of pandemic virus studies.
Parker previously served as the head of the National Science Advisory Board for Biosecurity (NSABB), a group of outside experts that advises NIH on biosecurity matters, and in that role recommended that Congress stand up a new government agency to advise on gain-of-function research. Former Centers for Disease Control and Prevention Director Robert Redfield has also endorsed moving gain-of-function research decision making out of the NIH to an independent commission.
“Given the well documented lapses in the NIH review process, policymakers should … remove final approval of any gain-of function research grants from NIH,” Redfield said in a February op-ed.
It remains to be seen whether the executive order will articulate carveouts for gain-of-function research without risks of harm such as research on non-replicative pseudoviruses, which can be used to study viral evolution without generating pandemic viruses.
It also remains to be seen whether the executive order will define “gain-of-function research” tightly enough to stand up to legal scrutiny should a violator be charged with a crime.
Risky research on coronaviruses funded by the NIH at the Wuhan Institute of Virology through the U.S. nonprofit EcoHealth Alliance typifies the loopholes in NIH’s existing regulatory framework, some biosecurity experts say.
Documents obtained through the Freedom of Information Act in 2023 indicated that EcoHealth Alliance President Peter Daszak submitted a proposal to the Pentagon in 2018 called “DEFUSE” describing gain-of-function experiments on viruses similar to SARS-CoV-2 but downplayed to his intended funder the fact that many of the tests would occur in Wuhan, China.
Daszak and EcoHealth were both debarred from federal funding in January 2025 but have faced no criminal charges.
“I don’t know that criminal penalties are necessary. But we do need more sticks in biosafety as well as carrots,” said a biosecurity expert who requested anonymity to avoid retribution from his employer for weighing in on the expected policy. “For instance, biosafety should be a part of tenure review and whether you get funding for future work.”
Some experts say that it is likely that the COVID-19 crisis was a lab-generated pandemic, and that without major policy changes it might not be the last one.
“Gain-of-function research on potential pandemic pathogens caused the COVID-19 pandemic, killing 20 million and costing $25 trillion,” said Richard Ebright, a Rutgers University microbiologist and longtime critic of high-risk virology, to the Daily Caller News Foundation. “If not stopped, gain-of-function research on potential pandemic pathogens likely will cause future lab-generated pandemics.”
-
2025 Federal Election1 day ago
Trump Has Driven Canadians Crazy. This Is How Crazy.
-
2025 Federal Election2 days ago
Carney’s Hidden Climate Finance Agenda
-
2025 Federal Election1 day ago
The Anhui Convergence: Chinese United Front Network Surfaces in Australian and Canadian Elections
-
2025 Federal Election1 day ago
Study links B.C.’s drug policies to more overdoses, but researchers urge caution
-
Automotive15 hours ago
Hyundai moves SUV production to U.S.
-
2025 Federal Election2 days ago
Conservatives promise to ban firing of Canadian federal workers based on COVID jab status
-
International2 days ago
Pope Francis Got Canadian History Wrong
-
2025 Federal Election2 days ago
When it comes to pipelines, Carney’s words flow both ways